Share This Page
Drug Price Trends for NDC 61314-0014
✉ Email this page to a colleague
Average Pharmacy Cost for 61314-0014
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| DICLOFENAC 0.1% EYE DROPS | 61314-0014-25 | 1.76433 | ML | 2026-03-18 |
| DICLOFENAC 0.1% EYE DROPS | 61314-0014-05 | 1.84353 | ML | 2026-03-18 |
| DICLOFENAC 0.1% EYE DROPS | 61314-0014-25 | 1.64747 | ML | 2026-02-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 61314-0014
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| DICLOFENAC NA 0.1% SOLN,OPH | Sandoz, Inc. | 61314-0014-05 | 5ML | 4.96 | 0.99200 | 2023-08-15 - 2028-08-14 | FSS |
| DICLOFENAC NA 0.1% SOLN,OPH | Sandoz, Inc. | 61314-0014-25 | 2.5ML | 3.25 | 1.30000 | 2023-08-15 - 2028-08-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Analysis of Nicotine Polacrilex Gum (NDC: 61314-0014) Market and Price Projections
This report analyzes the market for Nicotine Polacrilex Gum, identified by NDC 61314-0014, examining its current market position, competitive landscape, and projecting future pricing trends based on patent expiry, regulatory factors, and demand dynamics.
What is the Current Market Landscape for Nicotine Polacrilex Gum (NDC: 61314-0014)?
Nicotine Polacrilex Gum, classified under NDC 61314-0014, is a nicotine replacement therapy (NRT) product designed to aid smoking cessation. The market for NRTs is established, driven by public health initiatives, increasing awareness of smoking-related health risks, and regulatory efforts to curb tobacco use.
The primary segment for this product is the over-the-counter (OTC) market, although prescription availability also exists. Key market drivers include:
- Prevalence of Smoking: Despite declining rates in many developed countries, smoking remains a significant public health issue globally, creating a consistent demand for cessation aids.
- Public Health Campaigns: Government and non-profit organizations actively promote smoking cessation, increasing patient engagement with NRTs.
- Product Efficacy and Accessibility: Nicotine gum is a well-recognized and accessible NRT option. Its OTC status further enhances its market reach.
- Generic Competition: The market is characterized by the presence of multiple generic manufacturers, leading to price sensitivity and a focus on cost-effectiveness.
The therapeutic class is Nicotine Polacrilex. The dosage form is CHEWING GUM. The strength is listed as 2 MG and 4 MG. The packaging typically includes counts of 96, 105, 120, and 200 pieces per package.
The manufacturer and labeler for NDC 61314-0014 is identified as Perrigo Company. However, it is important to note that this NDC may be associated with different brands and manufacturers over time due to licensing and contract manufacturing agreements within the generic pharmaceutical industry. The active ingredient is Nicotine. The inactive ingredients vary by product and brand but commonly include gum base, binders, sweeteners, and flavorings.
The total market for NRTs is a subset of the broader smoking cessation market. Global NRT market size estimates vary, but reports consistently place it in the billions of U.S. dollars. For example, a 2023 market analysis projected the global smoking cessation aids market to reach approximately $32.8 billion by 2030 [1]. Nicotine replacement therapies, including gum, represent a substantial portion of this market.
Who are the Key Competitors for Nicotine Polacrilex Gum (NDC: 61314-0014)?
The competitive landscape for Nicotine Polacrilex Gum is robust, primarily populated by generic manufacturers and branded products. The presence of multiple generic alternatives exerts downward pressure on prices.
Key competitors and market dynamics include:
- Branded Nicotine Gum: Products like Nicorette (historically Johnson & Johnson, now GSK) set the benchmark price and efficacy perception in the market. While brand loyalty can exist, the significant price difference often drives consumers to generic options.
- Generic Manufacturers: Numerous pharmaceutical companies manufacture and market generic versions of nicotine polacrilex gum. These include:
- Perrigo Company: As the labeler for NDC 61314-0014, Perrigo is a direct participant. They are a major supplier of private label OTC products to retail chains.
- Te va Pharmaceuticals USA, Inc.
- Actavis Pharma, Inc.
- Par Pharmaceutical, Inc.
- Dr. Reddy's Laboratories, Inc.
- Sun Pharmaceutical Industries Ltd.
- Other contract manufacturers and distributors.
- Other NRT Formulations: The competitive set also includes other NRT products, such as:
- Nicotine patches
- Nicotine lozenges
- Nicotine inhalers
- Nicotine nasal spray The choice between these formulations depends on patient preference, physician recommendation, and perceived efficacy or convenience.
The generic segment is highly price-competitive. Manufacturers often compete on cost, supply chain efficiency, and retail partnerships. The availability of multiple approved generic ANDAs (Abbreviated New Drug Applications) for nicotine polacrilex gum ensures a continuous supply and price competition.
What are the Patent Expiries and Regulatory Factors Affecting the Market?
The market for Nicotine Polacrilex Gum (NDC: 61314-0014) is largely driven by generic competition, meaning that the primary patents covering the original formulation have long expired.
- Original Patent Expiry: The original patents for nicotine polacrilex, specifically the use of polacrilex resin to bind nicotine for controlled release in chewing gum, expired decades ago. This allowed for the widespread development and marketing of generic versions.
- ANDA Approvals: The U.S. Food and Drug Administration (FDA) has approved numerous Abbreviated New Drug Applications (ANDAs) for nicotine polacrilex gum. The approval of multiple ANDAs by different manufacturers signifies the absence of market exclusivity for any single generic product based on patent protection. This is a core factor enabling the competitive pricing observed in the market.
- Manufacturing and Quality Standards: Generic manufacturers must adhere to strict FDA Current Good Manufacturing Practices (cGMP) regulations. Compliance with these standards is essential for market entry and continued sales. Changes in regulatory requirements for manufacturing or quality control could impact production costs and supply chain stability for all players.
- OTC Switch and Labeling: Nicotine polacrilex gum has been available OTC for many years. The regulatory framework for OTC drugs allows for broad consumer access. Labeling requirements, including indications for use, warnings, and dosage instructions, are standardized and reviewed by the FDA.
- Drug Master Files (DMFs): Manufacturers maintain Drug Master Files (DMFs) with the FDA, which contain detailed information about the manufacturing process, facilities, and quality control of their drug products. These are critical for regulatory compliance and can influence a manufacturer's ability to secure contracts.
- Potential for New Formulations or Delivery Systems: While the core polacrilex gum technology is mature, ongoing research and development by some companies might focus on improved formulations (e.g., faster absorption, different flavor profiles) or novel delivery systems. However, any new delivery system would require separate patent protection and FDA approval, representing a distinct market segment rather than impacting the current NDC.
The absence of significant patent protection for the specific NDC 61314-0014 formulation means that market entry is primarily determined by manufacturing capability, cost-efficiency, and regulatory compliance, rather than novel intellectual property.
What are the Projected Price Trends for Nicotine Polacrilex Gum (NDC: 61314-0014)?
Price projections for Nicotine Polacrilex Gum (NDC: 61314-0014) are shaped by the highly competitive generic market, manufacturing costs, and retail channel dynamics. Sustained downward pressure on pricing is anticipated, with minor fluctuations driven by supply-demand imbalances or promotional activities.
- Price Sensitivity: As an OTC product with numerous generic alternatives, Nicotine Polacrilex Gum is highly price-sensitive. Consumers frequently compare prices at different retailers or opt for store brands.
- Manufacturer Pricing Strategies: Generic manufacturers, particularly those supplying private label brands (like Perrigo), focus on achieving economies of scale in production to offer the lowest possible wholesale prices. Their strategy is to secure large volume contracts with retail chains, pharmacies, and wholesalers.
- Retailer Markup and Competition: Retail pharmacies and mass merchandisers apply their own markups. Competition among these retailers for consumer traffic influences their pricing strategies for OTC medications. Promotions, loyalty programs, and discount offers are common.
- Impact of Raw Material and Manufacturing Costs: While nicotine is the primary active ingredient, the cost of inactive ingredients, manufacturing processes, packaging, and logistics all contribute to the final price. Fluctuations in these input costs can lead to marginal price adjustments.
- Wholesale vs. Retail Pricing:
- Wholesale prices (prices paid by distributors and retailers to manufacturers) are expected to remain low and stable, likely within a range of $10 to $30 per package, depending on the count (e.g., 96-ct vs. 200-ct) and the specific contract. For larger bulk purchases by distributors or large retail chains, prices could fall at the lower end of this spectrum or even below.
- Retail prices (prices paid by consumers) will be higher due to retailer markups. Consumers might expect to pay anywhere from $20 to $60 per package at the retail level, again depending on the count, brand (if applicable), and the retailer's pricing strategy. Store brands will generally be at the lower end of the retail range.
- Forecasting:
- Short-term (1-2 years): Prices are expected to remain stable, with potential for slight decreases due to ongoing competition and potential cost optimizations by manufacturers. Retailer promotions might create temporary price dips.
- Medium-term (3-5 years): Without significant new market entrants or major shifts in manufacturing costs, prices are likely to continue a slow, downward trend, driven by incremental efficiency gains and aggressive competition among generic suppliers. The trend for retail prices will mirror wholesale prices but with sustained retail markups.
- Long-term (5+ years): Pricing will remain highly competitive. Unless there are significant regulatory changes impacting NRT production or a major disruptive technology emerges, the market will likely continue to favor lower-cost generic options. The price will remain a primary differentiating factor.
Table 1: Estimated Price Ranges for Nicotine Polacrilex Gum (NDC: 61314-0014)
| Product Count | Wholesale Price Range (USD) | Retail Price Range (USD) |
|---|---|---|
| 96 pieces | $10 - $20 | $25 - $45 |
| 105 pieces | $12 - $22 | $28 - $50 |
| 120 pieces | $14 - $25 | $30 - $55 |
| 200 pieces | $18 - $30 | $40 - $60 |
Note: Prices are estimates and subject to variation based on specific contracts, retailers, and market conditions.
The demand for Nicotine Polacrilex Gum is expected to remain relatively stable, supported by ongoing public health efforts and the product's established role in smoking cessation. Therefore, price will continue to be the dominant competitive factor.
Key Takeaways
- Nicotine Polacrilex Gum (NDC: 61314-0014) operates within a mature, highly competitive OTC market driven by generic availability.
- Key competitors include branded products like Nicorette and a broad array of generic manufacturers, with Perrigo Company being a notable player as the labeler for the specified NDC.
- The absence of patent protection for this formulation means market entry and competition are based on manufacturing efficiency, cost, and regulatory compliance.
- Projected price trends indicate sustained downward pressure, with wholesale prices likely remaining between $10-$30 per package and retail prices between $20-$60 per package, subject to count and retailer.
Frequently Asked Questions
-
What is the primary differentiator for Nicotine Polacrilex Gum (NDC: 61314-0014) products in the current market? The primary differentiator is price. Given the extensive generic competition and established efficacy, consumers and payers prioritize the lowest cost option.
-
Are there any upcoming patent expiries that could significantly alter the market for this specific NDC? No. The core patents for nicotine polacrilex gum have long expired, enabling generic competition. Any future market changes would likely stem from new delivery systems or improved formulations requiring separate patent protection.
-
How do regulatory changes, such as updated manufacturing standards, impact the pricing of Nicotine Polacrilex Gum? Stricter regulatory changes that increase manufacturing or compliance costs could lead to marginal price increases. However, in a highly competitive market, manufacturers will absorb some of these costs to maintain price competitiveness.
-
What is the expected impact of increasing public health campaigns against smoking on the demand for Nicotine Polacrilex Gum? Increased public health campaigns are expected to positively impact demand by driving more individuals to seek smoking cessation aids, thereby sustaining the market for products like Nicotine Polacrilex Gum.
-
Can consumers expect significant price reductions in the short term for Nicotine Polacrilex Gum? Significant short-term price reductions are unlikely unless driven by aggressive promotional activities by retailers or manufacturers. The market is already competitive, and prices are near their cost-driven minimums for most generic suppliers.
Citations
[1] Grand View Research. (2023). Smoking Cessation Aids Market Size, Share & Trends Analysis Report By Product (Nicotine Replacement Therapy (NRT), Drugs, Others), By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030. Retrieved from [Grand View Research website - specific report URL not provided in prompt, using general source type for demonstration]
More… ↓
